Investor Ideas #Potcasts #Cannabis News
and Stocks on the Move: TSXV: $N.V,
TSXV: $OGI.V, CSE: $CHV.C
July 23 Potcast sponsored by Lexaria
Bioscience Corp. ( CSE: $LXX.C ) (OTC: $LXRP) a #Cannabis company with a new
disruptive drug delivery platform: DehydraTECH
Delta, BC –July 23, 2018 (Investorideas.com
Newswire) www.Investorideas.com, a global news source covering leading sectors
including marijuana and hemp stocks and its “potcast’ site, www.potcasts.ca release today’s edition of its series, Investorideas.com potcastsCM -
cannabis news and stocks to watch plus insight from thought leaders and experts.
July 23 Listen to the podcast:
Read this in full at http://www.investorideas.com/news/2018/cannabis/07234Potcasts-TSXV-N-OGI-CSE-CHV.asp
Today’s podcast overview/transcript:
Good morning and welcome to another Investorideas.com potcast ; looking
at cannabis news, stocks to watch as well as insights from thought leaders and
experts.
Today’s potcast was sponsored by Kelowna based Lexaria Bioscience Corp trading on the CSE under symbol LXX and on
the OTC as LXRP. Lexaria has developed a new disruptive
drug delivery platform: DehydraTECH The Company’s patented technology changes
the way Active Pharmaceutical Ingredients (“APIs”) enter the body orally:
1) Masks unwanted tastes – eliminates the need for sugar-filled edibles.
2) Reduces time of onset – effects are felt within 15-20 min vs. 60-120
min.
3) Avoids first-pass liver metabolism
4) Increases bio-absorption by 5-10X
The Company’s DehydraTECH™ technology is patent-protected for multiple
APIs: Cannabidiol (CBD), Tetrahydrocannabinol (THC), Non-steroidal
anti-inflammatory drugs (NSAIDs) such as ibuprofen, Nicotine and Fat soluble
vitamins.
Today’s podcast features news announcements from Namaste Technologies Inc. (TSXV::
N and OTCQB: NXTTF) , Organigram Holdings Inc. (TSX-V:
OGI and OTCQB:
OGRMF ) and
Canada House Wellness Group Inc. (
CSE : CHV).
But first,
Frost & Sullivan's recent analysis on medical cannabis finds that the total
revenue of this market in the United States is expected to grow from $5.32
billion in 2017 to $10 billion in 2022,
at a compound annual growth rate (CAGR) of 13.6%. Even though the Food and
Drug Administration (FDA) has approved only a few medical marijuana-derived
products, there will be a strong growth trajectory over the next few years.
Much of the current medical cannabis revenue is currently generated in states
where the use of marijuana plant products for medical indications has been
legalized. Revenue projections suggest that the medical segment of the market may surpass the recreational revenue segment in the
next four years, as patients in states where marijuana is legal look for alternatives
to opioids to treat their chronic pain.
"Several
pharmaceutical companies are working on the development of cannabidiol
(CBD)-based receptor agonist drugs. To do so, they need to be aware of the
guidelines the FDA sets for the approval of these drugs to advance the
therapeutics to the market," noted Barbara
Gilmore, Transformational Health
Senior Consultant at Frost & Sullivan. "The FDA advisory
committee recently approved a cannabinoid receptor agonist drug called
Epidiolex, which when launched will be the first FDA-approved, CBD-derived drug
on the US market for the treatment of epilepsy."
Namaste
Technologies Inc. announce the filing of its unaudited quarterly financial
statements, management's discussion and analysis and certification of the
quarterly filings for the third quarter of fiscal 2018. The statements for the
period can be accessed on the Company's SEDAR profile at www.sedar.com.
The
Company's net revenues for the three months ended May 31, 2018 were $4.1
million (2017 – $3.1 million), which is an increase of $1.0 million or 32% as
compared to the three months ended May 31, 2017. The increase in net revenues
during the third quarter of 2018 was primarily due to organic growth in the Company.
The
Company's net revenues for the nine months ended May 31, 2018 were $14.6
million (2017 – $7.1 million), which is an increase of $7.5 million or 106% as
compared to the nine months ended May 31, 2017 despite having divested the
Company's U.S. business in December 2017. The increase in net revenues during
the nine months ended May 31, 2018 was primarily due to revenue growth from
EDIT domains and Australian Vaporizers. EDIT domains were acquired in October
2016 and Australian Vaporizers was acquired in March 2017.
Namaste
Technologies Inc. also announced that the Company has submitted its application
to list its common shares on the NASDAQ Capital Market ("NASDAQ").
In advance
of the listing on NASDAQ, Namaste will file a Form 40-F Registration Statement
with the United States Securities and Exchange Commission. The listing of the
Company's common shares on NASDAQ remains subject to the approval of NASDAQ and
the satisfaction of all applicable listing and regulatory requirements, including
the effectiveness of the Form 40-F Registration Statement. The Company may also
seek shareholder approval for a share consolidation in order to meet the
share-price requirements of NASDAQ.
Organigram
Holdings Inc., the parent company of Organigram Inc., a leading licensed
producer of medical marijuana based in Moncton, New Brunswick, is in the final
stages of planting the remaining three of the sixteen three-tier Phase 3
cultivation rooms which have been licensed by Health Canada. In total, the Company's
Phase 3 expansion has increased Organigram's target dried flower equivalent
production capacity from an estimated 22,000 kg/annum (Phases 1 and 2) to
36,000 kg/annum (Phases 1, 2 and 3).
Staggered
harvests from Phase 3 are expected to begin in late August. The licensing of
Phase 3 does not require a new sales license as this expansion is part of
the existing Moncton facility. The additional capacity will help ensure
product is available for sale when the adult recreational market launches.
In addition,
Organigram has received licensing on a second harvest room which allows the
Company to automate its harvesting process. The Company has also received
licensing on new automated potting and waste shredding rooms.
Canada House
Wellness Group Inc. announced that its wholly owned subsidiary, Abba Medix
Corp. (“Abba”), a licensed
cannabis producer under the Access to
Cannabis for Medical Purposes Regulations (the "ACMPR") has successfully
completed its Health Canada pre-sales inspection and has received an amendment
to its Producer’s Licence from Health Canada to include the sale and provision
of marihuana seeds, effective July 20, 2018.
To support
this sales license Abba has secured an exclusive Canadian distribution
agreement with a well-established UK seed producer and now has access to more
than 800 cannabis strains. More than 200 of these strains are immediately
available for sale by Abba.
Investor ideas reminds
all listeners to read our disclaimers and disclosures on the
Investorideas.com website and this podcast is not an endorsement to buy
products or services or securities. Investors are reminded all investment
involves risk and possible loss of investment
Lexaria Bioscience Corp. has developed and
out-licenses its disruptive delivery technology that promotes healthier
ingestion methods, lower overall dosing and higher effectiveness of lipophilic
active molecules. Lexaria has multiple patents pending in over 40 countries
around the world and has patents granted in the USA and in Australia for
utilization of its DehydraTECHTM delivery technology. Lexaria's technology
provides increases in intestinal absorption rates; more rapid delivery to the
bloodstream; and important taste-masking benefits, for orally administered
bioactive molecules including cannabinoids, vitamins, non-steroidal
anti-inflammatory drugs (NSAIDs), nicotine and other molecules. www.lexariabioscience.com
Subscribe to the new cannabis podcast series:
Investorideas.com podcasts are also available on
iTunes, Google Play Music, Stitcher and Tunein.
Potcasts is now a certified word
mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires
Big Ideas
Investorideas.com is
a meeting place for global investors, featuring news, stock directories, video,
company profiles, interviews and more in leading sectors.
Investorideas.com
cannabis/marijuana and hemp content now includes http://cannabisstocknews.blogspot.com on Blogger.com: the
Investorideas.com news and stock directory pages, a cannabis investor group on
Linkedin.com , the 420 Cannabis Investor ideas www.420cannabisinvestorideas.com, and the new AI site Global Cannabis Investing at www.Globalcannabisinvesting.com
Disclaimer/Disclosure: Investorideas.com is
a digital publisher of third party sourced news, articles and equity research
as well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investment involves risk and possible loss of investment. This site is
currently compensated for news publication and distribution, social media and
marketing, content creation and more. Contact each company directly regarding
content and press release questions. Disclosure is posted for each compensated
news release, content published /created if required but otherwise the news was
not compensated for and was published for the sole interest of our readers and
followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure Lexaria
Bioscience Corp. ( CSE: LXX) (OTC: LXRP) is a media sponsor of the podcast
starting July 5 2018 more info
http://www.investorideas.com/About/News/Clientspecifics.asp
Additional info
regarding BC Residents and global Investors: Effective September 15 2008 - all
BC investors should review all OTC and Pink sheet listed companies for
adherence in new disclosure filings and filing appropriate documents with
Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations
of each country.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
Do you trade or invest in Marijuana / Hemp
Stocks? Check out our stock directory of
publicly traded CSE, TSX, TSXV, OTC, NASDAQ, NYSE, ASX
Marijuana / Hemp Stocks
Join our Group on Linkedin and talk about - Marijuana / Hemp Stocks - News and Trends in Green Investing
